Q3 2024 Veracyte Inc Earnings Call Transcript
Key Points
- Veracyte Inc (VCYT) reported a record Q3 revenue of $115.9 million, marking a 29% year-over-year growth.
- Testing revenue grew by 34% compared to the prior year, driven by strong volume and ASP improvements.
- Decipher delivered a record 21,250 tests in Q3, up 36% year-over-year, with growth across all NCCN and localized risk categories.
- The company raised its 2024 total revenue guidance to $442 million to $445 million, reflecting an improved outlook.
- Veracyte Inc (VCYT) achieved a Non-GAAP gross margin of 71%, up approximately 130 basis points compared to the prior year period.
- Product revenue was down 21% year-over-year due to ongoing supply challenges.
- BioPharma and other revenue decreased by 23% year-over-year.
- The company faces a $6 million headwind in 2025 due to the Envisia portfolio planning decision.
- Veracyte Inc (VCYT) decided to pause offering the Envisia test due to low penetration and high lifecycle management costs.
- The company is managing demand for its product line due to supply chain issues, leading to muted expectations for Q4 and 2025.
Good day. And thank you for standing by. Welcome to the Veracyte third quarter, 2024 conference call. At this time. All participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star one on your telephone and you will hear an automated message advising you your hand is raised to withdraw your question. Please press star one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Shayla Gorman, Senior Director of Investor Relations, Shayla, you have the floor.
Good afternoon everyone. And thank you for joining us today for a discussion of our third quarter 2024. Financial results with me today are Marc Stapley. Veracyte's Chief Executive Officer and Rebecca Chambers. Our Chief Financial Officer Veracyte issued a press release earlier this afternoon detailing our third quarter 2024 financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
